Role of cytokines and chemokines in itch

Handbook of Experimental Pharmacology

Volumn 226, Issue , 2015, Pages 163-176

  Storan, Eoin R ^a   O’Gorman, Susan M ^a   McDonald, Ian D ^a   Steinhoff, Martin ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Atopic dermatitis; Cell signaling; Cytokines; IL 31; Nerve; Oncostatin M; Pruritus; Receptor; Skin

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 31; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; ONCOSTATIN M; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; IL31 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNITY; CELL MIGRATION; CYTOKINE RELEASE; DISEASE COURSE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MICROGLIA; NERVE CELL; NEUROIMMUNOLOGY; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; PRURITUS; RECEPTOR AFFINITY; SCHWANN CELL; SIGNAL TRANSDUCTION; SKIN CELL; ANIMAL; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; CHEMOKINES; CYTOKINES; HUMANS; INTERLEUKINS; ONCOSTATIN M; PRURITUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927950678     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-662-44605-8_9     Document Type: Article

References (66)

1. Arai I, Tsuji M et al (2013) A single dose of interleukin-31 (IL-31) causes continuous itchassociated scratching behaviour in mice. Exp Dermatol 22(10):669–671
2. Arita K, South AP et al (2008) Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet 82(1):73–80
3. Bando T, Morikawa Y et al (2006) Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns. Neuroscience 142(4):1263–1271
4. Beck LA, Thaci D et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130–139
5. Bilsborough J, Leung DY et al (2006) IL-31 is associated with cutaneous lymphocyte antigenpositive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 117 (2):418–425
6. Boniface K, Diveu C et al (2007) Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 178(7):4615–4622
7. Brandt EB, Sivaprasad U (2011) Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2(3)
8. Cantrell DA, Smith KA (1984) The interleukin-2 T-cell system: a new cell growth model. Science 224(4655):1312–1316
9. Cevikbas F, Wang X et al (2014) A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 133 (2):448–460
10. Chan LS, Robinson N et al (2001) Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 117(4):977–983
11. Cheung PF, Wong CK et al (2010) Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol 22(6):453–467
12. Cremer B, Heimann A et al (1995) Pruritogenic effects of mitogen-stimulated peripheral blood mononuclear cells in atopic eczema. Acta Derm Venereol 75(6):426–428
13. Darsow U, Scharein E et al (1997) Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 137(3):415–417
14. Dillon SR, Sprecher C et al (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5(7):752–760
15. Diveu C, Lak-Hal AH et al (2004) Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw 15(4):291–302
16. Dreuw A, Radtke S et al (2004) Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J Biol Chem 279(34):36112–36120
17. Drory VE, Lev D et al (1998) Neurotoxicity of isolated limb perfusion with tumor necrosis factor. J Neurol Sci 158(1):1–4
18. Empl M, Renaud S et al (2001) TNF-alpha expression in painful and nonpainful neuropathies. Neurology 56(10):1371–1377
19. Fallahzadeh MK, Roozbeh J et al (2011) Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol Dial Transplant 26 (10):3338–3344
20. Feld M, Shpacovitch VM et al (2010) Interferon-gamma induces upregulation and activation of the interleukin-31 receptor in human dermal microvascular endothelial cells. Exp Dermatol 19 (10):921–923
21. Gaspari AA, Lotze MT et al (1987) Dermatologic changes associated with interleukin 2 administration. JAMA 258(12):1624–1629
22. George A, Schmidt C et al (1999) Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. Exp Neurol 160(1):124–132
23. Ghilardi N, Li J et al (2002) A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5. J Biol Chem 277(19):16831–16836
24. Grimstad O, Sawanobori Y et al (2009) Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 18(1):35–43
25. Grothe C, Heese K et al (2000) Expression of interleukin-6 and its receptor in the sciatic nerve and cultured Schwann cells: relation to 18-kD fibroblast growth factor-2. Brain Res 885 (2):172–181
26. Hamid Q, Boguniewicz M et al (1994) Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94(2):870–876
27. Hanisch UK (2002) Microglia as a source and target of cytokines. Glia 40(2):140–155
28. Hawro T, Saluja R et al (2014) Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy 69(1):113–117
29. Homey B, Steinhoff M et al (2006) Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 118(1):178–189
30. Imamachi N, Park GH et al (2009) TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci USA 106 (27):11330–11335
31. Kasraie S, Niebuhr M et al (2010) Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 65(6):712–721
32. Kasutani K, Fujii E, et al. (2014) Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice. Br J Pharmacol 171(22):5049–5058
33. Konishi H, Tsutsui H et al (2002) IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogenfree conditions. Proc Natl Acad Sci USA 99(17):11340–11345
34. Lacreusette A, Nguyen JM et al (2007) Loss of oncostatin Mreceptor beta in metastatic melanoma cells. Oncogene 26(6):881–892
35. Leyva-Castillo JM, Hener P et al (2013) Skin thymic stromal lymphopoietin initiates Th2 responses through an orchestrated immune cascade. Nat Commun 4:2847
36. Lippert U, Hoer A et al (1998) Role of antigen-induced cytokine release in atopic pruritus. Int Arch Allergy Immunol 116(1):36–39
37. Luger TA, Stadler BM et al (1981) Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). J Immunol 127(4):1493–1498
38. Madan V, Griffiths CE (2007) Systemic cyclosporine and tacrolimus in dermatology. Dermatol Ther 20(4):239–250
39. Martin HA (1996) Bradykinin potentiates the chemoresponsiveness of rat cutaneous C-fibre polymodal nociceptors to interleukin-2. Arch Physiol Biochem 104(2):229–238
40. Morikawa Y, Tamura S et al (2004) Essential function of oncostatin m in nociceptive neurons of dorsal root ganglia. J Neurosci 24(8):1941–1947
41. Neis MM, Peters B et al (2006) Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 118(4):930–937
42. Niyonsaba F, Ushio H et al (2010) Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 184(7):3526–3534
43. Nobbe S, Dziunycz P et al (2012) IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol 92(1):24–28
44. Nordlind K, Chin LB et al (1996) Immunohistochemical localization of interleukin-6-like immunoreactivity to peripheral nerve-like structures in normal and inflamed human skin. Arch Dermatol Res 288(8):431–435
45. Paus R, Schmelz M et al (2006) Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 116(5):1174–1186
46. Raby BA, Silverman EK et al (2003) Chromosome 12q harbors multiple genetic loci related to asthma and asthma-related phenotypes. Hum Mol Genet 12(16):1973–1979
47. Repovic P, Benveniste EN (2002) Prostaglandin E2 is a novel inducer of oncostatin-M expression in macrophages and microglia. J Neurosci 22(13):5334–5343
48. Schafers M, Sommer C et al (2008) Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience 157(2):414–423
49. Schulz F, Marenholz I et al (2007) A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol 120(5):1097–1102
50. Shubayev VI, Myers RR (2000) Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res 855(1):83–89
51. Silver JS, Hunter CA (2010) gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 88(6):1145–1156
52. Singer EM, Shin DB et al (2013) IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol 133 (12):2783–2785
53. Sonkoly E, Muller A et al (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117(2):411–417
54. Stander S, Steinhoff M (2002) Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 11(1):12–24
55. Steinhoff M, Bienenstock J et al (2006) Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 126(8):1705–1718
56. Steinhoff M, Cevikbas F, et al. (2012) Evaluation and management of a patient with chronic pruritus. J Allergy Clin Immunol 130(4): 1015–1016 e1017
57. Tamura S, Morikawa Y et al (2002) Expression of oncostatinMin hematopoietic organs. Dev Dyn 225(3):327–331
58. Tanaka M, Hara T et al (1999) Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor beta subunit. Blood 93(3):804–815
59. van Joost T, Stolz E et al (1987) Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol 123(2):166–167
60. Wagner R, Myers RR (1996) Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 7(18):2897–2901
61. Wahlgren CF, Scheynius A et al (1990) Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 70(4):323–329
62. Wahlgren CF, Tengvall Linder M et al (1995) Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 287(6):572–580
63. Wilson SR, The L et al (2013) The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155(2):285–295
64. Yamaoka K, Okayama Y et al (2009) Proteomic approach to FcepsilonRI aggregation-initiated signal transduction cascade in human mast cells. Int Arch Allergy Immunol 149(Suppl 1):73–76
65. Zhang JM, An J (2007) Cytokines, inflammation, and pain. Int Anesthesiol Clin 45(2):27–37
66. Zheng T, Oh MH et al (2009) Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 129(3):742–751